Latest NewsOct 30, 2025HiFiBiO Therapeutics Announces the Appointment of Leading I&I Experts to its Scientific Advisory BoardAll Filter By: Year20252024202320222021202020192018201720162015Nov 18, 2022HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsSep 5, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB301001 at 2022 ESMO CongressAug 15, 2022HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS® Selected Advanced Solid TumorsApr 27, 2022HiFiBiO Therapeutics to Present Trial in Progress Poster for HFB200301 at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingApr 18, 2022HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment< 1 … 4 5 6 7 8 … 18 >
